Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autogene cevumeran plus pembrolizumab in advanced melanoma
NCT03815058Phase 2Completed
- Sponsor
- Genentech
- Start
- Dec 2018
- Primary completion
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 6
01
Overview
A Phase 2 trial of autogene cevumeran in melanoma, sponsored by Genentech. Started Dec 2018; status: completed.
02
Drugs
autogene cevumeran
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03815058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815058.